ArticleDose-response : a publication of International Hormesis Society
DYNLRB1: A Potential Prognostic Biomarker Associated With an Immunosuppressive Microenvironment in Hepatocellular Carcinoma.
Article in Dose-response : a publication of International Hormesis Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate the expression pattern, prognostic significance, immune relevance, and biological function of Dynein Light Chain Roadblock-Type 1 (DYNLRB1) in hepatocellular carcinoma (HCC). Methods: Publicly available datasets and analytical platforms, including TCGA, GTEx, TIMER2.0, TISIDB, LinkedOmics, GEPIA2, CancerSEA, and the Human Protein Atlas, were utilized to evaluate DYNLRB1 expression, prognostic value, and immune infiltration characteristics. In vitro functional assays-including CCK-8, EdU incorporation, colony formation, wound-healing, and Transwell assays-were performed to validate the biological role of DYNLRB1 in HCC cells. Results: DYNLRB1 was significantly upregulated in HCC tissues and cell lines. Elevated DYNLRB1 expression was consistently associated with advanced clinicopathological features and poor survival outcomes across multiple metrics (including OS, DSS, DFI, and PFI). Furthermore, high DYNLRB1 expression correlated with an immunosuppressive tumor microenvironment signature, characterized by elevated inhibitory immune checkpoints. Functional enrichment suggested involvement in ribosome biogenesis and cell-cycle-associated processes. In vitro, DYNLRB1 knockdown significantly inhibited HCC cell proliferation, migration, and invasion. Conclusion: DYNLRB1 is a potential prognostic biomarker associated with tumor malignant progression and an immunosuppressive microenvironment in HCC. These findings suggest that DYNLRB1 may represent a potential therapeutic target warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.